TNF and systemic lupus erythematosus: Although TNFα agents such as infliximab are not included in the SLE treatment regimen in the updated EULAR, because of TNFα is known as Drugs-Induced Lupus (DIL), a case report of the use of TNFα in SLE patients with Ulcerative Colitis (UC) or Crohn’s disease (CD) resulted in no flare-up of SLE with CD remission, and modest efficacy was observed especially in patients UC with lupus nephritis, and no infliximab-induced SLE exacerbations were observed (Kearsley, 2000; Aringer et al., 2004; Principi et al., 2004; Aringer et al., 2009; Ben-Horin et al., 2016).